Burchert A, Bug G, Finke J, et al Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicenter sormain trial. Blood. 2018;132:661.
Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;JCO1903345.
gov. A study of ASP2215 (gilteritinib) by itself, ASP2215 combined with azacitidine or azacitidine by itself to treat adult patients who have recently been diagnosed with acute myeloid leukemia with a FLT3 gene mutation and who cannot receive standard chemotherapy. Accessed August 21, 2020. https://clinicaltrials.gov/ct2/show/NCT02752035
gov. A study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy (HOVON 156 AML). Accessed August 26, 2020.https://clinicaltrials.gov/ct2/show/NCT04027309
gov. A study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy, followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myedysplastic syndrome EB2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy (HOVON150AML). Accessed August 21, 2020. https://www.clinicaltrials.gov/ct2/show/NCT03839771
gov. A study to assess safety and efficacy of venetoclax in combination with gilteritinib in participants with relapsed/refractory acute myeloid leukemia. Accessed August 21, 2020. https://clinicaltrials.gov/ct2/show/NCT03625505
gov. A trial of the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib administered as maintenance therapy following allogeneic transplant for patients with FLT3/internal tandem duplication (ITD) acute myeloid leukemia (AML). Accessed August 21, 2020. https://clinicaltrials.gov/ct2/show/NCT02997202
gov. Efficacy of oral azacitidine plus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission (QUAZAR AML-001). https://clinicaltrials.gov/ct2/show/NCT01757535. Accessed August 21, 2020.
gov. Quizartinib with standard of care chemotherapy and as continuation therapy in patients with newly diagnosed FLT3-ITD (+) acute myeloid leukemia (AML) (QuANTUM-First). Accessed August 21, 2020. https://clinicaltrials.gov/ct2/show/NCT02668653
gov. Study of crenolanib vs midostaurin following induction chemotherapy and consolidation therapy in newly diagnosed FLT3 mutated AML. Accessed August 21, 2020. https://clinicaltrials.gov/ct2/show/NCT03258931
gov. Venetoclax and quizartinib in treating patients with FLT3-mutated recurrent or refractory acute myeloid leukemia. Accessed August 21, 2020. https://clinicaltrials.gov/ct2/show/NCT03735875
DAURISMO® (glasdegib) [prescribing information]. New York, NY: Pfizer Inc; Approved 2018. Revised March 2020.
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216-228.
DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791-803.
Gottardi M, Mosna F, de Angeli S, et al. Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. Hematol Rep. 2017;9:7029.
Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986-996.
Idhifa® (enasidenib) [prescribing information]. Summit, NJ: Celgene Corporation; Approved September 2017. Revised August 2017.
Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novoacute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113-119.
MYLOTARG® (gemtuzumab ozogamicin) [prescribing information]. Philadelphia, PA: Pfizer Inc; Approved 2000. Revised June 2020.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. Version 3.2020. Accessed August 21, 2020. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
ONUREG® (azacitidine) [prescribing information]. Summit, NJ: Celgene Corporation; Approved 2004. Revised September 2020.
Perl AE, Daver NG, Pratz KW, et al. Venetoclax in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia: a phase 1b study. 2019;134(suppl 1):3910.
Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728-1740.
Pratz KW, DiNardo CD, Arellano ML, et al. Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies. 2019;134(suppl 1):264.
Rausch CR, DiNardo CD, Maiti A, et al. Venetoclax dosing in combination with antifungal agents: real world experience in patients with acute myeloid leukemia. 2019;134(suppl 1):2640.
Roboz GJ, Dohner H, Pocock C, et al. Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC). J Clin Oncol. 2020;38:7533.
Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015; 16:1691-1699.
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464.
Tibsovo® (ivosidenib) [prescribing information]. Cambridge, MA: Agios Pharmaceuticals, Inc. May 2019.
VENCLEXTA® (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; Approved 2016. Revised May 2020.
Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578-1582.
Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Blood. 2019:134(suppl 2).
Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Presented at the 2019 ASH Annual Meeting, December 10, 2019; Orlando, FL. Abstract LBA-3.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Alexander Perl, MD

Associate Professor of Medicine
Division of Hematology Oncology
Perelman Center for Advanced Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Disclosure: Alexander Perl, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Actinium; Astellas; Daiichi Sankyo; Forma; Loxo; Syndax
Received grants for clinical research from: AbbVie; Astellas; Daiichi Sankyo; FujiFilm

Courtney D. DiNardo, MD

Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Disclosure: Courtney D. DiNardo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Agios; Celgene; Daiichi Sankyo; ImmuneOnc; Novartis; Takeda
Received grants for clinical research from: AbbVie; Agios; Celgene; Calithera; Daiichi Sankyo
Owns stock, stock options, or bonds from: Notable Labs

Daniel A. Pollyea, MD, MS

Associate Professor, Medicine-Hematology
Clinical Director of Leukemia Services
University of Colorado Cancer Center
Aurora, Colorado

Disclosures

Disclosure: Dan A. Pollyea, MD, MS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Amgen; Celgene; Genentech; Karyopharm; Syndax; Syros; Takeda
Received grants for clinical research from: AbbVie; Pfizer
Other: DSMB: Glycomimetics

Editors

Mindy Tanzola, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

Lisa Cockrell, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisa Cockrell, PhD, has disclosed no relevant financial relationships.

Jason Luis Quinones, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Jason Luis Quinones, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: IDRI

CME / ABIM MOC

Updates in the Frontline Treatment of Acute Myeloid Leukemia

Authors: Alexander Perl, MD; Courtney D. DiNardo, MD; Daniel A. Pollyea, MD, MS
CME / ABIM MOC Released: 9/22/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/22/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists.

The goal of this activity is to improve the knowledge of hematologists/oncologists about new agents used in the frontline management of acute myeloid leukemia (AML) and how to integrate these agents into clinical practice.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data for newer frontline AML therapies
Have greater competence related to
- Tailoring therapy for patients with newly diagnosed AML
- Managing treatment-related adverse events for patients with newly diagnosed AML

Disclosures

Faculty

Alexander Perl, MD

Associate Professor of Medicine
Division of Hematology Oncology
Perelman Center for Advanced Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Disclosure: Alexander Perl, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Actinium; Astellas; Daiichi Sankyo; Forma; Loxo; Syndax
Received grants for clinical research from: AbbVie; Astellas; Daiichi Sankyo; FujiFilm

Courtney D. DiNardo, MD

Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Disclosure: Courtney D. DiNardo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Agios; Celgene; Daiichi Sankyo; ImmuneOnc; Novartis; Takeda
Received grants for clinical research from: AbbVie; Agios; Celgene; Calithera; Daiichi Sankyo
Owns stock, stock options, or bonds from: Notable Labs

Daniel A. Pollyea, MD, MS

Associate Professor, Medicine-Hematology
Clinical Director of Leukemia Services
University of Colorado Cancer Center
Aurora, Colorado

Disclosures

Disclosure: Dan A. Pollyea, MD, MS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Amgen; Celgene; Genentech; Karyopharm; Syndax; Syros; Takeda
Received grants for clinical research from: AbbVie; Pfizer
Other: DSMB: Glycomimetics

Editors

Mindy Tanzola, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

Lisa Cockrell, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisa Cockrell, PhD, has disclosed no relevant financial relationships.

Jason Luis Quinones, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Jason Luis Quinones, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: IDRI

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

Clinical Advances in Acute Myeloid Leukemia

From Medscape Education Oncology

CME / ABIM MOC

Updates in the Frontline Treatment of Acute Myeloid Leukemia

Authors: Alexander Perl, MD; Courtney D. DiNardo, MD; Daniel A. Pollyea, MD, MSFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 9/22/2020

Valid for credit through: 9/22/2021, 11:59 PM EST

processing....

Assessment Survey

Before you begin, please answer the questions in this brief survey.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Alexander Perl, MD

Courtney D. DiNardo, MD

Daniel A. Pollyea, MD, MS

Editors

Mindy Tanzola, PhD

Lisa Cockrell, PhD

Jason Luis Quinones, PhD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC

Updates in the Frontline Treatment of Acute Myeloid Leukemia

Target Audience and Goal Statement

Disclosures

Faculty

Alexander Perl, MD

Courtney D. DiNardo, MD

Daniel A. Pollyea, MD, MS

Editors

Mindy Tanzola, PhD

Lisa Cockrell, PhD

Jason Luis Quinones, PhD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Updates in the Frontline Treatment of Acute Myeloid Leukemia

Assessment Survey